EDX Medical Group PLC, based in Cambridge, England, has announced a new step forward in the fight against testicular cancer by signing an exclusive agreement with mirdetect GmbH. This partnership allows EDX to distribute the innovative M371 blood test, which identifies critical biomarkers for early-stage testicular cancer, a prevalent condition among young men. The distribution will cover the UK, Sweden, Finland, Norway, and Denmark.
The M371 test aligns with EDX Medical’s mission to deliver digital diagnostic solutions targeting cancer, heart disease, and infectious diseases. By offering a tool for early detection, the test empowers healthcare professionals to make personalised and optimised treatment decisions, enhancing patient outcomes.
Expressing enthusiasm for the partnership, Chief Executive Officer Mike Hudson noted the synergy between the test and EDX’s existing diagnostics portfolio. He also highlighted plans to collaborate with mirdetect further, aiming to improve the test and associated services for broader healthcare benefits.
This agreement underscores EDX Medical’s commitment to advancing accessible, precise diagnostics that support better patient care.
EDX Medical Group Plc (AQSE:EDX) is a global specialist in digital clinical diagnostics; developing and supporting high-performance products and services to provide cost-effective prediction of disease risk, inform clinical decision-making, enable personalised healthcare and accelerate the development of new medicines for cancer, neurology, heart disease and infectious diseases.
